Katerina Chatzidionysiou

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Journal article: RMD OPEN. 2025;11(4):e005617
Multiple DMARD discontinuations in rheumatoid arthritis: how often and in what patients? Results from a national clinical RA register
Wettersand E; di Giuseppe D; Askling J; Chatzidionysiou K
Article: ARTHRITIS & RHEUMATOLOGY. 2025;77(3):253-262
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study
Eberhard A; Di Giuseppe D; Askling J; Bergman S; Bower H; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Olofsson T; Frisell T; Turesson C
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;:ard-2024-225982
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Sebbag E; Lauper K; Molina-Collada J; Aletaha D; Askling J; Gente K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao HM; Chatzidionysiou K; Curtis JR; Danlos F-X; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer AC; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg J-E
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;84(4):643-652
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Sebbag E; Molina-Collada J; Ndoye R; Aletaha D; Askling J; Gente K; Bertheussen H; Bitoun S; Bolek EC; Buch MH; Burmester GR; Canhao HM; Chatzidionysiou K; Curtis JR; Danlos F-X; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer AC; Schulze-Koops H; Sedmak N; Silva-Fernandez L; Szekanecz Z; Lauper K; Finckh A; Gottenberg J-E
Article: EUROPEAN JOURNAL OF CANCER. 2024;207:114172
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ; Burgers FH; Janssen JC; Putker AE; Veenstra SPGR; Hospers GAP; Aarts MJB; Hehenkamp KW; Doornebosch VLE; Verhaert M; van den Berkmortel FWPJ; Chatzidionysiou K; Llobell A; Barros M; Maria ATJ; Takeji A; García Morillo J-S; Lidar M; van Eijs MJM; Blank CU; Aspeslagh S; Piersma D; Kapiteijn E; Labots M; Boers-Sonderen MJ; van der Veldt AAM; Haanen JBAG; May AM; Suijkerbuijk KPM
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae063
Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years
Curtis JR; Wollenhaupt J; Tas SW; Chatzidionysiou K; Wang L; Roberts K; Tsekouras V
Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: LUPUS. 2024;33(6):615-628
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: MICROBIOLOGY SPECTRUM. 2024;12(4):e0298123-e02923
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)
Frodlund M; Nived P; Chatzidionysiou K; Soedergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M
Article: PLOS ONE. 2023;18(12):e0295838
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: RMD OPEN. 2023;9(4):e003648
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Lindstrom U; Turesson C; Chatzidionysiou K; Lindqvist E; Knight A; Forsblad-d'Elia H; Askling J
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52(6):591-600
Evaluation of an individually tailored smoking-cessation intervention for patients with rheumatoid arthritis in an outpatient clinic
Karlsson M-L; Hertzberg-Nyquist K; Saevarsdottir S; Lundberg IE; Demmelmaier I; Pettersson S; Chatzidionysiou K
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2023;41(10):1985-1990
Original research on Behçet's syndrome: a bibliometric analysis over 20 years (2000-2019)
Bolla E; Chatzidionysiou K; Tektonidou MG; Sfikakis PP
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(16):5377
Intracardiac Thrombi in Morbus Adamantiades-Behcet in Two Swedish Patients
Da Mutten R; Borg A; Chatzidionysiou K; Parodis I
Article: VACCINE. 2023;41(20):3247-3257
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
Frodlund M; Nived P; Chatzidionysiou A; Sodergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
Article: RHEUMATOLOGY. 2022;61(10):3952-3962
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindstrom U; Turesson C; Frisell T
Article: RMD OPEN. 2022;8(2):e002465
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
Chatzidionysiou K; di Giuseppe D; Soderling J; Catrina A; Askling J
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022;56:152050
Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis
Yang C; Williams RD; Swerdel JN; Almeida JR; Brouwer ES; Burn E; Carmona L; Chatzidionysiou K; Duarte-Salles T; Fakhouri W; Hottgenroth A; Jani M; Kolde R; Kors JA; Kullamaa L; Lane J; Marinier K; Michel A; Stewart HM; Prats-Uribe A; Reisberg S; Sena AG; Torre CO; Verhamme K; Vizcaya D; Weaver J; Ryan P; Prieto-Alhambra D; Rijnbeek PR
Article: RHEUMATOLOGY. 2022;61(9):3596-3605
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjowall C; Lindqvist E; Askling J
Article: RHEUMATOLOGY. 2022;61(9):3647-3656
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries
Di Giuseppe D; Lindstrom U; Aaltonen K; Relas H; Provan S; Gudbjornsson B; Hetland ML; Askling J; Kauppi M; Geirsson AJ; Chatzidionysiou K; Jorgensen TS; Dreyer L; Michelsen B; Jacobsson L; Glintborg B
Article: CRITICAL REVIEWS IN IMMUNOLOGY. 2022;42(4):21-36
Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective
Flores-Chavez A; Brito-Zeron P; Retamozo S; Bitoun S; Fisher BA; Liew D; Suijkerbuijk K; Chatzidionysiou K; Suarez-Almazor JM; Lambotte O; Mariette X; Ramos-Casals M
Article: RMD OPEN. 2021;7(3):e001987
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(10):1512-1518
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(8):1086-1093
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Bower H; Frisell T; Di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: RMD OPEN. 2021;7(2):e001662
Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
Chatzidionysiou K; Circiumaru A; Rethi B; Joshua V; Engstrom M; Hensvold A; af Klint E; Catrina A
Article: RHEUMATOLOGY. 2021;60(2):820-828
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg J-E; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordstrom DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2020;38(5):841-847
Validation of new classification criteria of rheumatoid arthritis in an international multicentre study
Li R; Sun X; Ye H; Liu J; Zhao J; Liu X; Mei Y; Zhang Z; Guo J; Bi L; Wang G; Leng X; Gu F; Sun L; Zou Q; Fang Y; Jiang Q; Chatzidionysiou K; Priya S; Janardana R; Nair A; Catrine AI; Danda D; Li ZG
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 2):247-252
The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future.
Koutsianas C; Chatzidionysiou K
Article: RMD OPEN. 2020;6(2):e001278
Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis
Joshua V; Hensvold AH; Reynisdottir G; Hansson M; Cornillet M; Nogueira L; Serre G; Nyren S; Karimi R; Eklund A; Skold M; Grunewald J; Chatzidionysiou K; Catrina A
Article: RMD OPEN. 2020;6(2):e001363
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordstrom D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
Article: RMD OPEN. 2020;6(2):e001183
Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study.
Najm A; Alunno A; Sivera F; Ramiro S; Haines C; Working Group on Training in Rheumatology across E
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813
Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: ARTHRITIS RESEARCH & THERAPY. 2020;22(1):56
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Panopoulos S; Chatzidionysiou K; Tektonidou MG; Bournia VK; Drosos AA; Liossis S-NC; Dimitroulas T; Sakkas L; Boumpas D; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Sidiropoulos P; Bertsias G; Vassilopoulos D; Sfikakis PP
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):87-91
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C; Flouri I; Fanouriakis A; Nikoloudaki M; Nikolopoulos D; Repa A; Boki K; Chatzidionysiou K; Garyfallos A; Boumpas D; Sidiropoulos P; Bertsias G
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):1-2
Mediterranean Journal of Rheumatology March 2020 Highlights.
Chatzidionysiou K
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20976975
Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis PP; Tektonidou MG
Article: RHEUMATOLOGY. 2019;58(12):2170-2176
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: JOURNAL OF DIABETES RESEARCH. 2019;2019:2936962-8
Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy
Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(1):17-23
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordstrom D; Canhao H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(6):465-474
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries
Glintborg B; Lindstrom U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MRK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(2):131-140
Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial
Emamikia S; Gentline C; Chatzidionysiou K; Arnaud L; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2018;5(1):e000287
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
Giannakou I; Chatzidionysiou K; Magder LS; Gyori N; van Vollenhoven R; Petri MA
Article: JOURNAL OF RHEUMATOLOGY. 2017;44(2):162-169
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration
Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge E-M; Pavelka K; Gabay C; Scherer A; Nordstrom D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Victoria Hernandez M; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2017;4(1):e000192
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
Gyori N; Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven RF; Petri M
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):314
Differences and similarities in rheumatology speciality training programmes across European countries (vol 74, pg 1183, 2015)
Sivera F; Ramiro S; Cikes N
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):213
Rheumatology training experience across Europe: analysis of core competences
Sivera F; Ramiro S; Cikes N; Cutolo M; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45(sup128):64-75
Optimizing biological treatments for rheumatoid arthritis
Chatzidionysiou K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(7):1336-1342
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Gabay C; Riek M; Hetland ML; Hauge E-M; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; Lukina G; Nordstrom DC; Lie E; Ancuta I; Victoria Hernandez M; van Riel PLMC; van Vollenhoven R; Kvien TK
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:50
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Article: RHEUMATOLOGY. 2016;55(2):230-236
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Article: RMD OPEN. 2016;2(2):e000323
Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
Emamikia S; Arkema EV; Gyori N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
Article: RMD OPEN. 2016;2(1):e000133
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Chatzidionysiou K; Turesson C; Teleman A; Knight A; Lindqvist E; Larsson P; Coster L; Forslind K; van Vollenhoven R; Heimburger M
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(6):431-437
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register
Chatzidionysiou K; Kristensen L-E; Eriksson J; Askling J; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1183-1187
Differences and similarities in rheumatology specialty training programmes across European countries
Sivera F; Ramiro S; Cikes N; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(5):890-896
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R
Journal article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2013;102(3):233-241
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
Journal article: КЛИНИЧЕСКАЯ ПРАКТИКА. 2013;10(3):233-236
Latest developments in the treatment of rheumatoid arthritis: is there new hope for patients?
Chatzidionysiou K; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2013;42(3):190-195
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
Chatzidionysiou K; van Vollenhoven RF
Article: LANCET. 2012;379(9827):1712-1720
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):374-377
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Article: BMJ OPEN. 2012;2(5):e001524
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
Kastbom A; Coster L; Arlestig L; Chatzidionysiou A; van Vollenhoven RF; Padyukov L; Rantapaa-Dahlqvist S; Saevarsdottir S
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(10):1822-1825
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
Raza K; Stack R; Kumar K; Filer A; Detert J; Bastian H; Burmester GR; Sidiropoulos P; Kteniadaki E; Repa A; Saxne T; Turesson C; Mann H; Vencovsky J; Catrina A; Chatzidionysiou A; Hensvold A; Rantapaa-Dahlqvist S; Binder A; Machold K; Kwiakowska B; Ciurea A; Tamborrini G; Kyburz D; Buckley CD
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(9):1575-1580
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(3):469-475
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam SA; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF
Article: LANCET. 2009;374(9688):459-466
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Coster L; Waltbrand E; Zickert A; Theander J; Thorner A; Hellstrom H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wornert M; Bratt J
Visa fler

Alla övriga publikationer

Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3773-3774
Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Manolakou T; Boddul S; Sentis G; Panagias MA; Samiotaki M; Nikolopoulos D; Slipicevic A; Sanjiv K; Henriksson M; Mortusewicz O; Chatzidionysiou A; Jakobsson P-J; Helleday T
Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s688-s689
Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Svedman FC; Liapi M; Chatzidionysiou A; Mansson-Broberg A; Brage SE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1164-1165
AN UNUSUAL INITIAL PRESENTATION OF VEXAS SYNDROME
Galindo-Feria AS; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:29
EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER
Sebbag E; Lauper K; Collada JM; Aletaha D; Askling J; Benesova K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao H; Chatzidionysiou K; Curtis J; Danlos FX; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer A; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg JE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:856
SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER
Sebbag E; Molina Collada J; Lauper K; Aletaha D; Askling J; Benesova K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao H; Chatzidionysiou K; Curtis J; Danlos FX; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer A; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg JE
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:533
THE IMPACT OF IMMUNOMODULATING TREATMENT ON THE SEROLOGICAL IMMUNOGENICITY FOLLOWING THREE DOSES OF COVID-19 VACCINE AND PERSISTENCE OF IMMUNOGENICITY OF TWO VACCINE DOSES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES - A SWEDISH STUDY (COVID19-REUMA)
Frodlund M; Nived P; Chatzidionysiou K; Sodergren A; Klingberg E; Hansson M; Pin E; Klareskog L; Kapetanovic MC
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:863
SERONEGATIVE RHEUMATOID ARTHRITIS (RA) - IS IT REALLY RA?
Wettersand EB; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:2053-2054
RISK FACTORS FOR DEVELOPING RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS AFTER IMMUNOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS
Liapi M; Chatzidionysiou K
Review: RMD OPEN. 2023;9(1):e002898
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
van der Togt CJT; van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaac J; Mulleman D; Verschueren P; Vulto AG; Welsing PMJ; Verhoef L; den Broeder AA
Review: ANNALS OF THE RHEUMATIC DISEASES. 2023;82(1):3-18
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Smolen JS; Landewe RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg J-E; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(8):e141
Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al
Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(8):e140
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al.
Bettiol A; Pregnolato F; Sciascia S; Emmi G; Prisco D; Meroni PL
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:1017
TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-INDUCED INFLAMMATORY ARTHRITIS AND POLYMYALGIA RHEUMATICA
Liapi M; Chatzidionysiou K
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:588
RECOMMENDATIONS FOR COST-EFFECTIVE USE OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN INFLAMMATORY ARTHRITIS: RESULTS FROM AN INTERNATIONAL DELPHI STUDY
Van der Togt C; Van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaacs J; Mulleman D; Verschueren P; Vulto A; Welsing P; Verhoef LM; Den Broeder A
Review: BIOMEDICINE & PHARMACOTHERAPY. 2022;148:112687
Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy
Jensen AK; Chatzidionysiou K; Torp CK; Sorensen AS; Tenstad HB; Schafer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
Editorial comment: FRONTIERS IN MEDICINE. 2022;9:1020859
Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases.
Md Yusof MY; Alivernini S; Chatzidionysiou K
Review: LAKARTIDNINGEN. 2021;118:21114
[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].
Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Corrigendum: JOURNAL OF DIABETES RESEARCH. 2021;2021:9827150-1
Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy (vol 2019, 2936962, 2019)
Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Review: CLINICAL RHEUMATOLOGY. 2021;40(5):1687-1695
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 1):120-128
Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium.
Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:1004
COMPARATIVE RISK OF CANCER ASSOCIATED WITH FIRST-LINE DMARDS USE IN RHEUMATOID ARTHRITIS: REAL WORLD EVIDENCE FROM THE OHDSI NETWORK
Duarte-Salles T; Recalde M; Weaver J; Burn E; Marinier K; Diaz Y; Illingens B; Vizcaya D; Chatzidionysiou K; Ryan P; Prieto-Alhambra D
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:134
DEVELOPMENT AND VALIDATION OF PATIENT-LEVEL PREDICTION MODELS FOR ADVERSE HEALTH OUTCOMES AMONGST ADULT RA PATIENTS INITIATING FIRST-LINE TREATMENT OF METHOTREXATE MONOTHERAPY: A MULTINATIONAL REAL-WORLD COHORT ANALYSIS INCLUDING 164,735 SUBJECTS
Yang C; Williams R; Swerdel J; Jani M; Duarte-Salles T; Chatzidionysiou K; Prieto-Alhambra D; Ryan P; Rijnbeek P
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:331
FIRST LINE TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: A MULTINATIONAL POPULATION-BASED COHORT FROM 14 REAL WORLD HEALTHCARE DATABASES AND 9 COUNTRIES - REALITY VERSUS GUIDELINES
Sena AG; Granados D; Hughes N; Fakhouri W; Hottgenroth A; Kolde R; Reisberg S; Torre CO; Duarte-Salles T; Diaz Y; Golib-Dzib JF; Brouwer ES; Burn E; Lane J; Vizcaya D; Wirta SB; De Wilde M; Verhamme K; Rijnbeek P; Theander E; Chatzidionysiou K; Prieto-Alhambra D; Ryan P
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:762-763
SIMILAR CARDIOVASCULAR COMORBIDITY AND HIGHER DEPRESSION RATES IN PSORIATIC ARTHRITIS COMPARED TO AGE- AND SEX-MATCHED RHEUMATOID ARTHRITIS AND DIABETES MELLITUS PATIENTS
Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis P; Tektonidou M
Letter: LUPUS SCIENCE & MEDICINE. 2020;7(1):e000415
Could severe COVID-19 be considered a complementopathy?
Chatzidionysiou K; Svenungsson E; Faustini F
Review: CLINICAL RHEUMATOLOGY. 2020;39(3):957-961
Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?
Fragoulis GE; Chatzidionysiou K
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(2):304-307
Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus
Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
Review: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2019;33(5):101476
Established rheumatoid arthritis - Redefining the concept
Chatzidionysiou K; Fragoulis GE
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus
Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2019;30(2):103-109
Rheumatic disease and artistic creativity.
Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:703-704
EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND RITUXIMAB) AFTER FAILURE OF NON-TNFI BIOLOGIC DMARD IN RHEUMATOID ARTHRITIS - COLLABORATION BETWEEN FIVE NATIONAL REGISTERS
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Aaltonen K; Trokovic N; Kristianslund E; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782
ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761
PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:1800
ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE
Panopoulos S; Tektonidou M; Chatzidionysiou K; Drosos A; Liossis S-N; Dimitroulas T; Sakkas L; Boumpas D; Sidiropoulos P; Bertsias G; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Vassilopoulos D; Sfikakis P
Corrigendum: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(3):258
Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients (vol 48, pg 178, 2019)
Glintborg B; Lindstrom U; Aaltonen K; Kristianslund E; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland M; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MEK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Review: RMD OPEN. 2019;5(2):e000993
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
Chatzidionysiou K; Sfikakis PP
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:891
SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB
Chatzidionysiou K; Engstrom M; af Klint E; Hensvold A; Catrina AI
Review: ANNALS OF THE RHEUMATIC DISEASES. 2018;77(4):476-479
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
Radner H; Chatzidionysiou K; Nikiphorou E; Gossec L; Hyrich KL; Zabalan C; van Eijk-Hustings Y; Williamson PR; Balanescu A; Burmester GR; Carmona L; Dougados M; Finckh A; Haugeberg G; Hetland ML; Oliver S; Porter D; Raza K; Ryan P; Santos MJ; van der Helm-van Mil A; van Riel P; von Krause G; Zavada J; Dixon WG; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2018;77:A39-A40
SIGNIFICANT DECREASE OF T-CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB
Chatzidionysiou K; Engstrom M; Af Klint E; Hensvold A; Catrina AI
Corrigendum: RMD OPEN. 2018;4(1)
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (vol 4, e000655, 2018)
Chatzidionysiou K; Hetland ML; Frisell T
Review: RMD OPEN. 2018;4(1):e000655
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Aaltonen K; Tormanen MRK; Kristianslund EK; Kvien TK; Provan SA; Guobjornsson B; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson L; Askling J
Corrigendum: RMD OPEN. 2018;4(1):rmdopen-2018-000655corr1
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (vol 4, e000655, 2018)
Chatzidionysiou K; Hetland ML; Frisell T
Conference publication: SWISS MEDICAL WEEKLY. 2017;147:3S
Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-TNF mode of action?
Finckh A; Courvoisier DS; Gottenberg J-E; Mariette X; Morel J; Bergstra SA; Hernandez V; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland M; Chatzidionysiou K; Askling J; Turesson C; Gabay C; Van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:69-70
PREDICTORS OF PERSISTENT DISEASE ACTIVITY AND PERSISTENT LONG QUIESCENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS - RESULTS FROM THE HOPKINS LUPUS COHORT
Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:1027
HOW DO WE USE BIOLOGICS IN PATIENTS WITH A HISTORY OF MALIGNANCY? AN ASSESSMENT OF TREATMENT PATTERNS USING SCANDINAVIAN REGISTERS
Chatzidionysiou K; Aaltonen K; Nordstrom D; Gudbjornsson B; Grondal G; Geirsson AJ; Steingrimsdottir L; Frisell T; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:567
DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION?
Finckh A; Courvoisier D; Gottenberg J-E; Marlette X; Morel J; Bergstra SA; Hernandez V; Codreanu C; Kviens TK; Santos MJ; Pavelka K; Hetland M; Chatzidionysiou K; Askling J; Turesson C; Gabay C; Van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:517-518
DETERMINING MINIMUM CLINICALLY IMPORTANT CHANGE IN MULTI BIOMARKER DISEASE ACTIVITY SCORE ASSOCIATED WITH CLINICAL IMPROVEMENT IN METHOTREXATE NAIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Chatzidionysiou K; Hensvold AH; Saevarsdottir S; Bolce RJ; Chernoff D; Hwang CC; Wang X; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:686
PRESCRIPTION PATTERNS OF TUMOUR NECROSIS FACTOR INHIBITOR AND USTEKINUMAB IN PSORIATIC ARTHRITIS: A NORDIC POPULATION-BASED COHORT STUDY
Jorgensen TS; Dreyer L; Gudbjornsson B; Hetland ML; Glintborg B; Askling J; Chatzidionysiou K; Di Giuseppe D; Jacobsson L; Wallman JK; Kristianslund EK; Olsen IC; Fagerli K; Lie E; Nordstrom D; Aaltonen K; Joensuu J; Love TJ; Geirsson AJ; Kristensen LE
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:341-342
PRESCRIPTION PATTERNS OF BIOLOGICAL DISEASE MODIFYING DRUGS AND BIOSIMILARS IN ANKYLOSING SPONDYLITIS - A COLLABORATION BETWEEN BIOLOGICAL REGISTERS IN THE FIVE NORDIC COUNTRIES
Glintborg B; Chatzidionysiou K; Askling J; Aaltonen K; Kristianslund E; Gudbjornsson B; Nordstrom D; Hetland ML; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Kvien T; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Jacobsson L
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1102-1107
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of The EULAR recommendations for the management of rheumatoid arthritis
Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewe R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1101-1136
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewe RBM
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):1113-1136
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewe R
Review: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(6):960-977
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Smolen JS; Landewe R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg J-E; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poor G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Review: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):251
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
Nikiphorou E; Radner H; Chatzidionysiou K; Desthieux C; Zabalan C; van Eijk-Hustings Y; Dixon WG; Hyrich KL; Askling J; Gossec L
Corrigendum: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):144
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (vol 18, 50, 2016)
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:406-407
TOWARDS DEVELOPMENT OF A MINIMUM CORE DATASET AND STANDARDS OF DATA COLLECTION FOR OBSERVATIONAL RHEUMATOID ARTHRITIS RESEARCH A EULAR INITIATIVE
Radner H; Nikiphorou E; Chatzidionysiou K; Gossec L; Hyrich K; Filip C; van Eijk-Hustings Y; Williamson P; Dixon W; Askling J
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:166
THE EULAR TASK FORCE FOR STANDARDISING MINIMUM DATA COLLECTION IN RHEUMATOID ARTHRITIS OBSERVATIONAL RESEARCH: RESULTS OF A HIERARCHICAL LITERATURE REVIEW
Chatzidionysiou K; Nikiphorou E; Gossec L; Hyrich K; Filip C; van Eijk-Hustings Y; Williamson P; Dixon W; Askling J; Radner H
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:499
INDUCTION-MAINTENANCE IN EARLY RA: A META-ANALYSIS OF TRIALS USING MTX PLUS TNF-INHIBITOR AS INDUCTION THERAPY
Emamikia S; Arkema EV; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:477-478
ASSOCIATION BETWEEN NUMBER AND TYPE OF DIFFERENT ACPA FINE SPECIFICITIES AND PARENCHYMAL LUNG CHANGES IN HIGH RESOLUTION COMPUTED TOMOGRAPHY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
Joshua V; Chatzidionysiou K; Reynisdottir G; Hensvold AH; Hansson M; Nogueira L; Eklund A; Serre G; Grunewald J; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:299-300
RELATIONSHIP BETWEEN CORTICOSTEROIDS AND UNFAVORABLE MEDICAL EFFECTS. A STUDY UNDER THE SHARE SYSTEM BASED ON THE CLINICAL TRIAL BELIMUMAB IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (BLISS-76)
Emamikia S; Gentline C; Backheden M; Chatzidionysiou K; Arnaud L; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:477
RISK FOR LUNG CANCER IN RA AND DIFFERENT RA PHENOTYPES: RESULTS FROM A POPULATION-BASED CASE-CONTROL STUDY
Chatzidionysiou K; Reynisdottir G; Joshua V; Frisell T; Askling J; Catrina A
Corrigendum: CURRENT OPINION IN RHEUMATOLOGY. 2016;28(2):1
The lung in rheumatoid arthritis, cause or consequence? Erratum.
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:A79
RISK FOR LUNG CANCER IN RA AND DIFFERENT RA PHENOTYPES: RESULTS FROM A POPULATION-BASED CASE-CONTROL STUDY
Chatzidionysiou K; Reynisdottir G; Joshua V; Frisell T; Askling J; Catrina AI
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:484-485
SMOKING AND RESPONSE TO RITUXIMAB IN ANTI-CCP POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS - RESULTS FROM AN INTERNATIONAL EUROPEAN COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Hauge E; Pavelka K; Gabay C; Nordstrom D; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Ancuta I; Kvien T; van Vollenhoven R; Saevarsdottir S
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:798-799
DISEASE ACTIVITY PATTERNS OVER TIME IN PATIENTS WITH SLE - A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF THE HOPKINS LUPUS COHORT
Gyori N; Chatzidionysiou A; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2015;74:492
RITUXIMAB DONE! WHAT'S NEXT IN RHEUMATOID ARTHRITIS? A EUROPEAN OBSERVATIONAL LONGITUDINAL STUDY ASSESSING THE EFFECTIVENESS OF BIOLOGICS AFTER RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(3):S65-S66
Disease activity patterns over time in patients with SLE - A retrospective descriptive analysis of the Hopkins Lupus Cohort
Gyori N; Chatzidionysiou A; Magder L; van Vollenhoven R; Petri M
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:601-602
RETENTION OF TOCILIZUMAB THERAPY: A COMPARISON BETWEEN TOCILIZUMAB IN MONOTHERAPY AND IN COMBINATION WITH DMARDS BASED ON THE TOCERRA COLLABORATION
Gabay C; Riek M; Hetland M; Hauge EM; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; van Vollenhoven R; Lukina G; Nordstrom D; Lie E; Ancuta I; Loza Santamaria E; van Riel P; Kvien T
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:674
EFFECTIVENESS OF REPEATED COURSES OF RITUXIMAB IN RA - RESULTS FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Pavelka K; Gabay C; Nordstrom DC; Canhao H; Tomsic M; van Riel PL; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:505-506
FIXED VERSUS ON-FLARE RETREATMENT WITH RITUXIMAB IN RA - RESULTS FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Pavelka K; Gabay C; Nordstrom DC; Canhao H; Tomsic M; van Riel PL; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven RF
Doctoral thesis: 2014
Biological therapy in rheumatoid arthritis : epidemiological studies
Chatzidionysiou A
Editorial comment: NATURE REVIEWS RHEUMATOLOGY. 2013;9(9):510-512
RHEUMATOID ARTHRITIS Triple therapy or etanercept after methotrexate failure in RA?
van Vollenhoven RF; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:517-518
TREATMENT WITH CERTOLIZUMAB PEGOL IN RA - DATA FROM THE NATIONAL REGISTRY ARTIS (ANTIRHEUMATIC THERAPIES IN SWEDEN)
Chatzidionysiou K; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:182
SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland M; Tarp U; Ancuta I; Pavelka K; Nordstrom D; Gabay C; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Kvien T; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2013;71:62
EFFICACY OF DIFFERENT DOSES OF RITUXIMAB FOR THE TREATMENT OF RA: DATA FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland M; Tarp U; Ancuta I; Pavelka K; Nordstrom D; Gabay C; Canhao H; Tomsic M; van Riel P; Gomez-Reino J; Kvien T; van Vollenhoven R
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2012;71:A14-U75
EFFICACY OF TNF SWITCH AFTER FAILURE OF ONE TNF INHIBITOR - RESULTS FROM A NATION-WIDE OBSERVATIONAL STUDY
Chatzidionysiou K; Eriksson J; Askling J; van Vollenhoven RF
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2012;71:a13-a14
EFFICACY OF DIFFERENT DOSES OF RITUXIMAB FOR THE TREATMENT OF RA: DATA FROM THE CERERRA COLLABORATION
Chatzidionysiou K; Lie E; Nasonov EL; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLC; Gomez-Reino JJ; Kvien TK; van Vollenhoven RF
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(6):614-625
When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K; van Vollenhoven RF
Visa fler

Forskningsbidrag

Optimal Treatment of Early Rheumatoid Arthritis: The NORD-STAR randomized trial embedded in the Swedish Rheumatology Quality Register SRQ: Combining Pragmatic Trials and National Registers...
Swedish Research Council
1 January 2015 - 31 December 2017

Anställningar

Adjungerad Lektor, Medicin, Solna, Karolinska Institutet, 2025-2027
Adjungerad Lektor, Medicin, Solna, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, reumatologi, Karolinska Institutet, 2020
Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2014

Handledning

Handledning till doktorsexamen
- Marie-Louise Karlsson, The impact of lifestyle changes, and treatment adherence in Early Rheumatoid Arthritis, 2023-

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Handledning

Handledning till doktorsexamen

Nyheter från KI

Kalenderhändelser från KI